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Abstract (Words: 234/250) 
Objectives: To examine the six-year prognosis of patients with late-life depression and to 
identify prognostic factors of an unfavorable course.  
Design and setting: The Netherlands Study of Depression in Older persons (NESDO) is a 
multi-site naturalistic prospective cohort study with six-year follow-up. 
Participants: 378 clinically depressed patients according to DSM-IV-TR criteria and 132 non-
depressed comparisons were included at baseline between 2007-2010. 
Measurements: Depression was measured by the Inventory of Depressive Symptoms at six-
month intervals and a diagnostic interview at two-year and six-year follow-up. Multinomial 
regression and mixed model analyses were both used to identify depression-related clinical, 
health and psychosocial prognostic factors of an unfavorable course. 
Results: Among depressed patients at baseline, 46.8% were loss to follow-up, 15.9% had an 
unfavorable course, i.e. chronic or recurrent, 24.6% had partial remission, and 12.7% had full 
remission, at six-year follow-up. The relative risk (RR) of mortality in depressed patients was 
2.5 (95%-CI:1.26-4.81) when compared with non-depressed comparisons. An unfavorable 
course of depression was associated with a younger age of depression onset, higher 
symptom severity of depression, pain, neuroticism, and loneliness at baseline. Additionally, 
partial remission was associated with chronic diseases, and loneliness at baseline when 
compared with full remission.  
Conclusions: The long-term prognosis of late-life depression is poor with regard to mortality 
and course of depression. Chronic diseases, loneliness, and pain may be used as putative 
targets for optimizing prevention and treatment strategies of relapse and chronicity. 
 
Key words: Depression; Old Age; Risk Factors; Prognosis; Outcome. 
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Introduction (Words: 558) 
Late-life depression is a complex and heterogeneous disorder, often accompanied by an 
unfavorable prognosis.1 It has been associated with a chronic course,2 a higher risk of 
subsequent development of cognitive impairment or dementia,3 and premature death.4 
Although late-life depression can be treated effectively, relapse and recurrence as well as 
chronicity are a major problem in daily practice. Studies on the long-term prognosis of late-
life depression are required to inform clinicians and to identify prognostic factors that may 
contribute to the improvement of treatment strategies and relapse prevention.   
An unfavorable prognosis of late-life depression has been demonstrated in both 
community samples,5–8 and clinical samples.9–14 Beekman et al. (2002) studied the six-year 
course of community-dwelling older adults with late-life depression, using both diagnostic 
interviews and self-reports, and found that 32% had a severe chronic course and 44% an 
unfavorable but fluctuating course, whereas only 23% showed remission.6 In our previous 
two-year follow-up study of the Netherlands Study of Depression in Older persons (NESDO), 
we found that nearly 50% of the clinically depressed patients still had a depression 
diagnosis, and 61% had a chronic course of depressive symptoms.13 It is known that 
depression in older adults is more likely to have a chronic or chronic-relapsing course 
compared to younger adults.2,15 Since meta-analyses of treatment studies have 
demonstrated equal efficacy of antidepressants among all ages,16 suboptimal maintenance 
treatment may be an explanation for the less favorable prognosis in older adults. Also, some 
specific depressive syndromes occur more often in later life, such as the depression-
executive dysfunction syndrome with apathy,17 which has particularly been linked to a poor 
outcome.18,19 
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Currently, there has been an increasing interest to identify distinct long-term 
trajectories of depressive symptoms using latent class analyses. Hybels et al. (2016) 
identified four trajectory classes in a clinical sample of depressed older adults after three-
years of follow-up, including a quick recovery class (43%), a persistent moderate symptom 
class (27%), a persistent high symptom class (15%), and a slow recovery class (15%).12 Higher 
perceived stress and lower social support were associated with the persistent high symptom 
class.12 These trajectories have proved to be useful in obtaining a better insight in the course 
of late-life depression, for example, by distinguishing a fast recovery class from a slow 
recovery class.12,20 However, its use for clinicians may be limited, for they rely on a 
depression diagnosis for the management of depression, not on depressive symptoms only.  
Multiple factors from different domains of functioning contribute to the onset and 
prognosis of depression.21 For clinical purpose, prognostic factors may be assigned to a 
depression-related clinical domain, a health and lifestyle domain, and a psychosocial 
domain. Several factors from these domains have been associated with an unfavorable 
course of depression, including comorbid anxiety,22 sleep problems,23 chronic diseases,13,15 
functional limitations,24 pain,25 loneliness,26 lack of social support,12 childhood trauma,27 and 
neuroticism.28 Whether these factors are also associated with the prognosis of depression 
on the long-term remains to be explored. 
The aim of the present study was twofold. First, the long-term prognosis of late-life 
depression was examined, in terms of both main reasons for attrition and course types, in 
clinically depressed patients over six-years. Second, prognostic factors of long-term course 
types were identified. We hypothesized that the long-term prognosis of late-life depression 
is poor, with a high mortality rate and an unfavorable course, including recurrence and 
chronicity, in most patients.  
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Methods (Words: 1284) 
Study Design 
The Netherlands Study of Depression in Older persons (NESDO) is a multi-site prospective 
cohort study designed to examine the course and consequences of depressive disorders in 
older adults (≥60 years). Sampling procedures have been previously described in detail.29 In 
short, data collection of the baseline measurement took place between 2007 and 2010. 
Depressed patients were recruited in five regions in the Netherlands from both mental 
health care facilities and general practitioners. Non-depressed comparisons were recruited 
from general practitioners and were included if they had no lifetime diagnosis of depression. 
Participants were excluded when they had a dementia diagnosis, or were suspected for 
dementia based on clinician’s judgment. Follow-up assessments by means of a face-to-face 
interview were performed two-years,13 and six-years after baseline using the same 
measurement instruments as at baseline. Additionally, postal assessments were performed 
every six-months, including a questionnaire on self-reported depressive symptoms. Well-
trained research assistants conducted the interviews. All interviews were audio taped and 
quality controlled. The research coordinator regularly evaluated interviews on the basis of 
their audiotapes. Question wording and probing behavior of interviewers were regularly 
monitored by checking a random selection of each interviewer. Written informed consent 
was obtained from all participants. NESDO’ study protocol has been approved centrally by 
the Ethical Review Board of the VU University Medical Center, and subsequently by the 
ethical review boards of the Leiden University Medical Center, University Medical Center 
Groningen, and the Radboud university medical center Nijmegen.  
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Sample 
At baseline, NESDO included 378 depressed patients, having major depressive disorder 
(n=265), dysthymia (n=6), double depression (n=94) (major depression and dysthymia) or 
minor depression (n=13) according to Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV-TR criteria),30 and 132 non-depressed comparisons, aged ≥ 60 years.13 Depressed 
patients did not differ from non-depressed comparisons with respect to mean age and sex, 
but depressed patients had less education, were more often divorced or widowed, and had 
lower cognitive functioning. From the 510 respondents at baseline, 401 were retained in the 
two-year follow-up assessment with an overall attrition rate of 21.4%.13  
 
Measurements 
Depression 
The DSM-IV-TR-diagnosis of major depression, dysthymia and minor depression was 
assessed with the Composite Interview Diagnostic Instrument (CIDI, WHO, version 2.1) at 
two- and six-year of follow-up.30 Severity of depressive symptoms was measured by a postal 
assessment every six months as a continuous variable with the Inventory of Depressive 
Symptoms (IDS),31 which is a 30-item self-report scale that was developed to assess all core 
criterion diagnostic depressive symptoms. The IDS scores range between 0 and 84 with 
higher scores indicating more severe depression. An IDS score < 14 was defined as no 
depression.32 The scale has acceptable psychometric properties in depressed outpatients,31 
and depressed inpatients.32 Cronbach’s alpha for the IDS in our sample was 0.83.  
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Course types 
The course types were categorized according to the two-year and six-year measurement 
into: a) full remission, b) partial remission, c) recurrent, and d) chronic, using both the 
symptom severity level (according to the IDS) and diagnosis of depression (according to the 
DSM-IV-TR). Full remission was defined as the absence of a depression diagnosis at six-year 
follow-up, combined with an IDS score < 14 at six-year follow-up (at measurement cycles 12 
and 13, thereby covering six months). Partial remission was defined as the absence of a 
depression diagnosis at six-year follow-up, but with an IDS score ≥ 14 at six-year follow-up 
(at measurement cycle 12 and 13). Absence of a depression diagnosis at two-year, but 
presence of a diagnosis at six-year was labeled as ‘recurrent’. Presence of a depression 
diagnosis both at two- and six-year follow-up was labeled as ‘chronic’. The last two 
categories (recurrent and chronic) were based on diagnosis of depression according to the 
CIDI only.  
 
Prognostic factors 
Demographics were assessed using standard questions and included sex, age, and 
educational level (years). The following depression-related clinical factors were included: 
previous episode of depression, age of onset of depression and comorbid anxiety diagnosis 
(y/n) were assessed by the CIDI, severity of depressive symptoms was assessed by the IDS,31 
severity of anxiety symptoms was assessed by the Beck Anxiety Index (BAI),33 global 
cognitive functioning was assessed by the Mini Mental State Examination (MMSE),34 apathy 
was assessed by the Apathy Scale (AS),35 sleep problems was assessed by the Women’s 
Health Initiative Insomnia Rating Scale (WHIIRS),36 use of antidepressants and frequent use 
of benzodiazepines were assessed by inspection of the medication. The following health and 
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lifestyle factors were included: chronic physical diseases were self-reported and assessed by 
the LASA Questionnaire (LAPAQ),37 functional limitations were assessed by the WHO-
Disability Assessment Scale II (WHODAS 2.0),38 metabolic syndrome was assessed by the 
original ATP-III criteria,39 chronic pain was assessed by the Chronic Graded Pain Scale 
(CPGS),40 body-mass-index was measured by weight (kg)/squared height (m2), physical 
activity was assessed by the International Physical Activities Questionnaire (IPAQ) and 
dichotomized (low versus moderate/high),41 smoking was assessed by asking current 
smoking behavior (y/n), and alcohol use was assessed by Alcohol Use Disorders 
Identification (AUDIT).42 The following psychosocial factors were included: neuroticism was 
assessed by the NEO-Five Factor Inventory (NEO-FFI),43 childhood trauma was assessed by 
the Netherlands Mental Health Survey and Incidence Study (NEMESIS) Questionnaire,44 
partner status (y/n) was asked, loneliness was assessed by the Rasch-Type Loneliness Scale 
(RTLS),45 social support was assessed by the Close Person Inventory and dichotomized (poor: 
< 2 confidents versus good: ≥ 2 confidents),46 and recent life events were assessed by the 
Brugha Questionnaire.47 
 
Statistical Analyses 
First, descriptive analyses were used to describe attrition and its determinants in the patient 
group (eTable 1). For both the patient group and non-depressed comparison group, attrition 
rates were calculated by dividing the proportion of respondents that were loss to follow-up 
with the total number of respondents at baseline. Subsequently, bivariate and multivariate 
logistic regression analyses were used to identify determinants of attrition (eTable 2). 
Second, study sample characteristics were described according to the ‘course of late-life 
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depression’, in which the groups ‘recurrent’ and ‘chronic’ were combined to ensure equal 
group sizes for the purpose of subsequent statistical analyses (Table 1).  
A correlation matrix was derived for the independent variables to rule out 
multicollinearity. A Pearson correlation cutoff of 0.70 was used to determine whether 
substantial correlation was present, and whether variables had to be left out of subsequent 
analysis. No correlation > 0.70 was found between all the independent variables. The highest 
correlations observed were between BAI and neuroticism (0.52), BAI and WHODAS 2.0 
(0.45). Also, the correlations between the independent variables at baseline and the 
dependent variable IDS at baseline, and at two-year and six-year follow-up, were retrieved. 
At baseline, none of the variables was correlated with IDS at > 0.70. The highest correlations 
observed were between IDS and WHODAS 2.0 (0.69), IDS and BAI (0.56), and IDS and 
neuroticism (0.54). 
Bivariate multinomial regression analyses were performed to investigate the 
association between each prognostic factor and ‘course of late-life depression’, using ‘full 
remission’ as reference group (Table 2). An additional analysis was performed using ‘partial 
remission’ as reference group for the comparison with a chronic/recurrent (unfavorable) 
course. To overcome the study’s statistical power problem, multivariate analyses were 
performed using Linear Mixed Models with the longitudinally measured ‘symptom severity 
of depression’ (IDS) as dependent variable (Table 3). First, group wise multivariate analyses 
were conducted for each of the three separate domains. Subsequently, the final multivariate 
model contained all prognostic factors that were associated with IDS at p<.05 from the 
group wise multivariate analyses. The goodness of fit for all multivariate models was 
evaluated with the -2 Log Likelihood (-2LL) method by comparing the fitted fixed-effects 
models to the model with no predictors (null model). We evaluated changes in the -2LL 
 10 
 
between the null model and each fitted fixed-effects model. Analyses were performed using 
IBM SPSS 22.0.        
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Results (Words: 550) 
Attrition of NESDO 
Figure 1 contains the flowchart of NESDO. From the 510 respondents at baseline, 299 
participated in the six-year follow-up assessment with an overall attrition rate of 41.4%. The 
attrition rate between two- and six-year follow-up was 25.4%. The attrition rates for the 
patient and comparison group differed at 46.8% and 25.8%, respectively. The most 
important reasons for attrition in the patient group were mortality (16.4%) and mental 
reasons (15.1%), mainly cognitive impairment, whereas the most important reason for 
attrition in the non-depressed comparison group was refusal (9.1%). A total of seventy 
participants (13.7%) died during six-year follow-up, including sixty-two depressed patients 
and eight non-depressed comparisons. The relative risk of mortality among depressed 
patients was 2.47 time (95% CI: 1.26-4.81) higher when compared with non-depressed 
comparisons, χ2(1) = 8.84, p=.003. 
Among depressed patients, attrition was the same for men and women, χ2(1) = 0.78, 
p=.38 (eTable 1). In bivariate analyses (eTable 2), determinants of attrition in the patient 
group were higher age (OR: 1.08, 95%-CI: 1.05-1.11), less education (OR: 0.93, 95%-CI: 0.87-
0.98), a higher age of onset of depression (OR: 1.01, 95%-CI: 1.00-1.02), worse cognitive 
functioning (OR: 0.79, 95%-CI: 0.71-0.88), and less physical activity (OR: 2.01, 95%-CI: 1.28-
3.15). In multivariate analyses, age (OR: 1.06, 95%-CI: 1.03-1.09) and global cognitive 
functioning (OR: 0.83, 95%-CI: 0.75-0.95) remained significantly associated with attrition in 
the patient group. 
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Prognosis of late-life depression  
Among the total of 378 depressed patients at baseline, 177 (46.8%) were loss to follow-up, 
60 (15.9%) had a recurrent or chronic depression, 93 (24.6%) had a partial remission and 
only 48 (12.7%) had a full remission at six-year follow-up. Of those with a full remission at six 
years, 43.8% reached this after two years.  
Table 1 shows the characteristics from 201 clinically depressed patients who were 
able to participate in the study over the full six years according to their course type. This 
sample consisted of 137 (68.2%) women, and the mean age of the sample was 69.0 (SD: 6.5) 
years. Sixty (29.9%) depressed patients had an unfavorable course type (8.0% recurrent, 
21.9% chronic), 93 (46.3%) had a partial remission, and 48 (23.9%) had a full remission. The 
symptom severity levels of depression (IDS) at six-month intervals according to the prognosis 
of depressed patients after six-year follow-up is shown in Figure 2. 
 
Prognostic factors 
In Table 2, results from bivariate analyses demonstrate that the depression-related clinical 
factors: younger age of onset of depression, higher severity of depression, higher severity of 
anxiety, and more apathy; the health and lifestyle factors: chronic diseases, functional 
limitations, and chronic pain; and the psychosocial factors: neuroticism and loneliness were 
all associated with an unfavorable course type as compared to full remission. As compared 
to full remission, partial remission was only associated with chronic diseases and loneliness, 
and not with any of the depression-related clinical factors. As compared to partial remission, 
an unfavorable course type was associated with a younger age of onset of depression, 
higher severity of depression, a comorbid anxiety disorder, higher severity of anxiety, use of 
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antidepressants, functional limitations, less physical activity, less alcohol use, and 
neuroticism.  
From multivariate longitudinal analyses (Table 3), a younger age of onset of 
depression, higher severity of depression, chronic pain, neuroticism, and loneliness at 
baseline were significantly associated with higher levels of depression over the six-year 
follow-up.  
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Discussion (Words: 1124) 
The most important conclusion to be drawn from this study among depressed older patients 
is that the long-term prognosis for this group is poor in terms of mortality and course of 
depression. Attrition in the patient group was almost twice as high as in the comparison 
group. During six-years of follow-up, nearly 47% of the depressed patients were loss to 
follow-up, mainly due to mortality (relative risk of 2.5 versus non-depressed comparisons) 
and cognitive impairment. Sixteen percent had an unfavorable course type, i.e. chronic or 
recurrent, 25% had a partial remission, and only 13% had a full remission. Nonetheless, 
almost half of those reaching full remission at six-year follow-up still had clinically relevant 
depression at two-year follow-up, which is an important finding and should encourage 
clinicians to prolong and optimize treatment in depressed older patients, even after two 
years.  
We also demonstrated that results were biased in the direction of a more favorable 
prognosis if attrition was excluded as outcome, as this may lead to a selection of the more 
healthy and motivated patients (30% would have had an unfavorable course, 46% partial 
remission and 24% full remission). Furthermore, strict criteria were used to define full 
remission, as a result of which the proportion of patients with a full remission may be 
underestimated. The rationale for this decision was based on the previous finding that 
residual symptoms have been associated with a poor outcome,48,49 indicating that the goal 
must be to keep the patient as symptom-free as possible.48  
In a longitudinal study of 127 depressed older patients in the community, it was 
shown that at three years, 30% had died, 35% had a chronic or recurrent depression, 25% 
had another mental illness, and only 10% had maintained a full remission.5 Stek et al. (2002) 
examined the long-term prognosis of major depression in hospitalized older patients six to 
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eight year after clinical treatment and found that 40% had died, while among the survivors 
33% had no residual symptoms or relapses,11 which approximately corresponds to our 
finding that among survivors 24% reached full remission. These numbers from both 
community and clinical studies are in line with our results and strongly indicate that 
depression in later life is a disabling chronic disorder with a poor outcome.  
Depression is a complex multifactorial disease, implicating that multiple factors from 
different domains of functioning contribute to its onset and prognosis.21 This study found 
that an unfavorable course of depression was associated with a younger age of onset of 
depression, a higher severity of depression, chronic pain, neuroticism, and loneliness, which 
is in accordance with current literature.4,26,28,50,51 Furthermore, partial remission could not 
be distinguished from full remission using depression-related clinical factors, but was more 
likely associated with chronic diseases and loneliness. This finding could imply that these 
factors are important targets for interventions to prevent relapse, as partial remission is a 
strong predictor of relapse and chronicity.52 Our findings do not point to single factors that 
may be important for the prognosis of depression, but rather point to multiple factors from 
different domains of functioning that all are important, with each factor having a small but 
significant contribution.  
Recently, Brown et al. (2017) found that biological age was more important than 
chronological age in predicting the incidence and course of depressive symptoms over long-
term follow-up.53 The authors stated that their findings support the evolving biological view 
of late-life depression as resulting from deleterious age-associated changes.53,54 Our study 
suggests however that a more holistic view allowing identification of non-biological factors 
as well, is appropriate in targeting older adults at risk for an unfavorable prognosis and thus 
for prevention and treatment interventions.21,50  
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Our study has some limitations. First, because of a lack of power, multivariate 
analyses were not performed on course types, making it difficult to clarify the strongest 
prognostic factors of an unfavorable course type. On the other hand, we did perform 
multivariate analyses using mixed models with the IDS as assessed every six months, which 
allowed a more accurate assessment of prognostic factors. Second, there might be a great 
chance of a Type I error due to multiple statistical comparisons. However, on a theoretical 
basis, we included multiple factors from biopsychosocial domains of functioning that have 
been previously associated with a poor outcome of late-life depression in studies to date, 
thereby minimizing the risk of Type I error (or chance). Also, most of the variables that 
remained statistically significant (p<0.05) in the final multivariate model, had a stronger 
association with the outcome in the preceding groupwise models at p≤0.01 (except for ‘age 
of onset’). Furthermore, predictors that were associated with a poor outcome from 
multinomial regression analyses, are more or less the same predictors that were associated 
with a poor outcome from mixed model analyses, which should affirm the validity of our 
findings. Moreover, the factors uncovered in this study are in line with previous research, 
from which we think that our results are solid and accurate. Third, although the strength of 
NESDO is that the results generalize to clinical practice, they are not generalizable to the 
community. Moreover, in the Netherlands general practitioners provide primary care for 
depression. Depressed patients who do not recover are subsequently referred to specialist 
mental health care. This situation may have induced some selection bias in our sample, with 
relatively many patients with a treatment-resistant depression. Finally, by using depression 
diagnosis at two measurement points over six years, information was lacking on short-term 
relapses and recurrences in between these measurements. Since recurrence and chronicity 
are both unfavorable outcomes, this limitation was tackled by combining both groups. For 
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future research, a latent class analysis on the IDS data would provide more detailed 
information about detailed trajectories of depression.  
Despite of the limitations, the study has numerous strengths. The prognosis of late-
life depression was captured based on the depression diagnosis according to DSM-criteria in 
combination with the IDS at separate measurement points over six years, which increases 
the external validity and usability for clinicians. Furthermore, we did not only examine the 
course, but also attrition among patients with late-life depression, which made it 
additionally clear that the long-term prognosis of late-life depression is poor.  
The clinical implication of this study may be that a multidimensional approach 
targeting the uncovered factors is valuable in improving the prognosis of late-life depression. 
Depressed patients with a partial remission might benefit further from interventions 
targeting chronic diseases and loneliness to obtain full recovery. At the same time, the risk 
of a poor outcome, such as chronicity, cognitive impairment, or death may be inevitable in 
depressed patients when their depression is more severe, started at a younger age, and if 
health and psychosocial problems also exist. Careful long-term monitoring of depression 
among older adults may be key in optimizing maintenance treatment strategies.    
 18 
 
Acknowledgements 
Author Contributions: H.W. Jeuring, MD, had full access to all of the data in the study and 
takes responsibility for the integrity of the data and the accuracy of the data analysis. 
Study concept and design: Comijs, Oude Voshaar, Van der Mast, Naarding, Stek, Beekman 
Acquisition, analysis, or interpretation of data: All authors 
Drafting of the manuscript: Jeuring 
Critical revision of the manuscript for important intellectual content: All authors 
Administrative, technical or material support: Comijs, Beekman  
Study supervision: Comijs, Stek, Huisman, Beekman 
Funding/Support: The infrastructure for the NESDO study (http://nesdo.amstad.nl) is 
funded through the Fonds NutsOhra (project 0701-065), Stichting tot Steun VCVGZ, NARSAD 
The Brain and Behaviour Research Fund (grand ID 41080), and the participating universities 
and mental health care organizations (VU University Medical Center, Leiden University 
Medical Center, University Medical Center Groningen, UMC St. Radboud, and GGZ InGeest, 
GG Net, GGZ Nijmegen and Parnassia).  
Role of the Funder/Sponsor: The sponsor had no role in the design and conduct of the 
study; collection, management, analysis, and interpretation of the data; preparation, review, 
or approval of the manuscript; or decision to submit the manuscript for publication. 
Conflict of Interest Disclosures: None. 
Additional contributions: We thank participants and interviewers of the NESDO study.   
 19 
 
References 
1.  Power C, Greene E, Lawlor BA. Depression in Late Life: Etiology, Presentation, and 
Management. Ment Heal Illn Elder. 2017:1-31. doi:10.1007/978-981-10-0370-7_10-1. 
2.  Haigh EAP, Bogucki OE, Sigmon ST, Blazer DG. Depression Among Older Adults: A 20-
Year Update on Five Common Myths and Misconceptions. Am J Geriatr Psychiatry. 
June 2017. doi:10.1016/j.jagp.2017.06.011. 
3.  Singh-Manoux A, Dugravot A, Fournier A, et al. Trajectories of Depressive Symptoms 
Before Diagnosis of Dementia. JAMA Psychiatry. 2017;74(7):712. 
doi:10.1001/jamapsychiatry.2017.0660. 
4.  Blazer DG. Depression in late life: Review and commentary. J Gerontol. 
2003;58(3):249-265. doi:10.1093/gerona/58.3.M249. 
5.  Denihan A, Kirby M, Bruce I, Cunningham C, Coakley D, Lawlor BA. Three-year 
prognosis of depression in the community-dwelling elderly. Br J Psychiatry. 
2000;176(MAY):453-457. doi:10.1192/bjp.176.5.453. 
6.  Beekman ATF, Geerlings S, Deeg D, et al. The Natural History of Late-Life Depression. 
Arch Gen Psychiatry. 2002;59(July 2002):605-611. doi:10.1001/archpsyc.59.7.605. 
7.  Henderson AS, Korten AE, Jacomb PA, et al. The course of depression in the elderly: a 
longitudinal community-based study in Australia. Psychol Med. 1997;27(1):119-129. 
doi:10.1017/S0033291796004199. 
8.  Sharma VK, Copeland JR, Dewey ME, Lowe D, Davidson I. Outcome of the depressed 
elderly living in the community in Liverpool: a 5-year follow-up. Psychol Med. 
1998;28(6):1329-1337. http://www.ncbi.nlm.nih.gov/pubmed/9854274. 
9.  Brodaty H, Luscombe G, Peisah C, Anstey K, Andrews G. A 25-year longitudinal, 
comparison study of the outcome of depression. Psychol Med. 2001;31(8):1347-1359. 
doi:10.1017/S0033291701004743. 
10.  Lyness JM, Caine ED, King D a, Conwell Y, Duberstein PR, Cox C. Depressive disorders 
and symptoms in older primary care patients: one-year outcomes. Am J Geriatr 
Psychiatry. 2002;10(3):275-282. http://www.ncbi.nlm.nih.gov/pubmed/11994214. 
11.  Stek ML, Van Exel E, Van Tilburg W, Westendorp RGJ, Beekman ATF. The prognosis of 
depression in old age: Outcome six to eight years after clinical treatment. Aging Ment 
Heal. 2002;6(3):282-285. doi:10.1080/13607860220142413. 
12.  Hybels CF, Pieper CF, Blazer DG, Steffens DC. Heterogeneity in the three-year course 
 20 
 
of major depression among older adults. Int J Geriatr Psychiatry. 2016;31(7):775-782. 
doi:10.1002/gps.4391. 
13.  Comijs HC, Nieuwesteeg J, Kok R, et al. The two-year course of late-life depression; 
results from the Netherlands study of depression in older persons. BMC Psychiatry. 
2015;15(1):20. doi:10.1186/s12888-015-0401-5. 
14.  Katon WJ, Fan M-Y, Lin EHB, Unützer J. Depressive symptom deterioration in a large 
primary care-based elderly cohort. Am J Geriatr psychiatry. 2006;14(3):246-254. 
doi:10.1097/01.JGP.0000196630.57751.44. 
15.  Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle 
age: A systematic review of comparative studies. Am J Psychiatry. 2005;162(9):1588-
1601. doi:10.1176/appi.ajp.162.9.1588. 
16.  Kok RM, Reynolds CF. Management of Depression in Older Adults. JAMA. 
2017;317(20):2114. doi:10.1001/jama.2017.5706. 
17.  Alexopoulos GS, Kiosses DN, Klimstra S, Kalayam B, Bruce ML. Clinical Presentation of 
the “Depression–Executive Dysfunction Syndrome” of Late Life. Am J Geriatr 
Psychiatry. 2002;10(1):98-106. doi:10.1097/00019442-200201000-00012. 
18.  Groeneweg-Koolhoven I, Ploeg M, Comijs HC, et al. Apathy in early and late-life 
depression. J Affect Disord. 2017;223:76-81. doi:10.1016/j.jad.2017.07.022. 
19.  Yuen GS, Bhutani S, Lucas BJ, et al. Apathy in late-life depression: Common, 
persistent, and disabling. Am J Geriatr Psychiatry. 2015;23(5):488-494. 
doi:10.1016/j.jagp.2014.06.005. 
20.  Rhebergen D, Lamers F, Spijker J, de Graaf R, Beekman ATF, Penninx BWJH. Course 
trajectories of unipolar depressive disorders identified by latent class growth analysis. 
Psychol Med. 2012;42(7):1383-1396. doi:10.1017/S0033291711002509. 
21.  Blazer DG, Hybels CF. Origins of depression in later life. Psychol Med. 2005;35(9):1241. 
doi:10.1017/S0033291705004411. 
22.  Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment 
response and relapse risk in late-life depression: Controlled study. Br J Psychiatry. 
2007;190(APR.):344-349. doi:10.1192/bjp.bp.106.027169. 
23.  Kennedy GJ, Kelman HR, Thomas C. Persistence and remission of depressive 
symptoms in late life. Am J Psychiatry. 1991;148(2):174-178. 
doi:10.1176/ajp.148.2.174. 
 21 
 
24.  Bruce ML. Depression and disability in late life: directions for future research. Am J 
Geriatr Psychiatry. 2001;9(2):102-112. doi:10.1097/00019442-200105000-00003. 
25.  Karp JF, Weiner D, Seligman K, et al. Body Pain and Treatment Response in Late-Life 
Depression. Am J Geriatr Psychiatry. 2005;13(3):188-194. doi:10.1097/00019442-
200503000-00003. 
26.  Holvast F, Burger H, De Waal MMW, Van Marwijk HWJ, Comijs HC, Verhaak PFM. 
Loneliness is associated with poor prognosis in late-life depression: Longitudinal 
analysis of the Netherlands study of depression in older persons. J Affect Disord. 
2015;185:1-7. doi:10.1016/j.jad.2015.06.036. 
27.  Wielaard I, Comijs HC, Stek ML, Rhebergen D. Childhood Abuse and the Two-Year 
Course of Late-Life Depression. Am J Geriatr Psychiatry. 2017;25(6):633-643. 
doi:10.1016/j.jagp.2017.01.014. 
28.  Manning KJ, Chan G, Steffens DC. Neuroticism Traits Selectively Impact Long Term 
Illness Course and Cognitive Decline in Late-Life Depression. Am J Geriatr Psychiatry. 
2017;25(3):220-229. doi:10.1016/j.jagp.2016.10.006. 
29.  Comijs H, Van Marwijk H, Van der Mast R, et al. The Netherlands study of depression 
in older persons (NESDO); a prospective cohort study. BMC Res Notes. 2011;4(1):524. 
doi:10.1186/1756-0500-4-524. 
30.  American Psychiatric Association. American Psychiatric Association: Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Am Psychiatr 
Assoc. 2000. doi:10.1176/appi.books.9780890423349. 
31.  Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive 
Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477. 
doi:10.1017/S0033291700035558. 
32.  Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, 
Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of 
Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in 
public sector patients with mood disorders: a psych. Psychol Med. 
2004;34(1):S0033291703001107. doi:10.1017/S0033291703001107. 
33.  Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: 
Psychometric properties. J Consult Clin Psychol. 1988;56(6):893-897. 
doi:10.1037/0022-006X.56.6.893. 
 22 
 
34.  Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res. 
1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6. 
35.  Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. 
Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J 
Neuropsychiatry Clin Neurosci. 1992;4(2):134-139. doi:10.1176/jnp.4.2.134. 
36.  Levine DW, Kaplan RM, Kripke DF, Bowen DJ, Naughton MJ, Shumaker SA. Factor 
structure and measurement invariance of the Women’s Health Initiative Insomnia 
Rating Scale. Psychol Assess. 2003;15(2):123-136. doi:10.1037/1040-3590.15.2.123. 
37.  Kriegsman DMW, Penninx BWJH, van Eijk JTM, Boeke AJJP, Deeg DJH. Self-reports and 
general practitioner information on the presence of chronic diseases in community 
dwelling elderly. J Clin Epidemiol. 1996;49(12):1407-1417. doi:10.1016/S0895-
4356(96)00274-0. 
38.  Chwastiak LA, Von Korff M. Disability in depression and back pain: Evaluation of the 
World Health Organization Disability Assessment Schedule (WHO DAS II) in a primary 
care setting. J Clin Epidemiol. 2003;56(6):507-514. doi:10.1016/S0895-4356(03)00051-
9. 
39.  Marijnissen RM, Smits JEMP, Schoevers RA, et al. Association between metabolic 
syndrome and depressive symptom profiles—Sex-specific? J Affect Disord. 
2013;151(3):1138-1142. doi:10.1016/j.jad.2013.07.029. 
40.  Von Korff M, Miglioretti DL. A prognostic approach to defining chronic pain. Pain. 
2005;117(3):304-313. doi:10.1016/j.pain.2005.06.017. 
41.  Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 
12-Country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381-1395. 
doi:10.1249/01.MSS.0000078924.61453.FB. 
42.  Babor TF, Kranzler HR, Lauerman RJ. Early detection of harmful alcohol consumption: 
Comparison of clinical, laboratory, and self-report screening procedures. Addict 
Behav. 1989;14(2):139-157. doi:10.1016/0306-4603(89)90043-9. 
43.  Costa Jr. PT, McCrae RR. Domains and Facets: Hierarchical Personality Assessment 
Using the Revised NEO Personality Inventory. J Pers Assess. 1995;64(1):21-50. 
doi:10.1207/s15327752jpa6401_2. 
44.  De Graaf R, Bijl R V., Ten Have M, Beekman ATF, Vollebergh WAM. Pathways to 
 23 
 
comorbidity: The transition of pure mood, anxiety and substance use disorders into 
comorbid conditions in a longitudinal population-based study. J Affect Disord. 
2004;82(3):461-467. doi:10.1016/j.jad.2004.03.001. 
45.  de Jong-Gierveld J, Kamphuls F. The Development of a Rasch-Type Loneliness Scale. 
Appl Psychol Meas. 1985;9(3):289-299. doi:10.1177/014662168500900307. 
46.  Stansfeld S, Marmot M. Deriving a survey measure of social support: The reliability 
and validity of the close persons questionnaire. Soc Sci Med. 1992;35(8):1027-1035. 
doi:10.1016/0277-9536(92)90242-I. 
47.  Brugha T, Bebbington P, Tennant C, Hurry J. The List of Threatening Experiences: a 
subset of 12 life event categories with considerable long-term contextual threat. 
Psychol Med. 1985;15(1):189-194. doi:10.1017/S003329170002105X. 
48.  Judd LL. Dimensional paradigm of the long-term course of unipolar major depressive 
disorder. Depress Anxiety. 2012;29(3):167-171. doi:10.1002/da.21934. 
49.  Meeks TW, Vahia I V., Lavretsky H, Kulkarni G, Jeste D V. A tune in “a minor” can “b 
major”: A review of epidemiology, illness course, and public health implications of 
subthreshold depression in older adults. J Affect Disord. 2011;129(1-3):126-142. 
doi:10.1016/j.jad.2010.09.015. 
50.  Fiske A, Wetherell JL, Gatz M. Depression in Older Adults. Annu Rev Clin Psychol. 
2009;5(1):363-389. doi:10.1146/annurev.clinpsy.032408.153621. 
51.  Tunvirachaisakul C, Gould RL, Coulson MC, et al. Predictors of treatment outcome in 
depression in later life: A systematic review and meta-analysis. J Affect Disord. 
2017;227:164-182. doi:10.1016/j.jad.2017.10.008. 
52.  Steffens DC, McQuoid DR, Krishnan KRR. Partial response as a predictor of outcome in 
geriatric depression. Am J Geriatr Psychiatry. 2003;11(3):340-348. 
http://www.ncbi.nlm.nih.gov/pubmed/12724113. 
53.  Brown PJ, Wall MM, Chen C, et al. Biological Age, Not Chronological Age, is Associated 
with Late Life Depression. Journals Gerontol Ser A. August 2017. 
doi:10.1093/GERONA/GLX162. 
54.  Rutherford BR, Taylor WD, Brown PJ, Sneed JR, Roose SP. Biological aging and the 
future of geriatric psychiatry. Journals Gerontol - Ser A Biol Sci Med Sci. 
2016;72(3):343-352. doi:10.1093/gerona/glw241. 
 24 
 
Figure legends 1 
Figure 1: Flowchart of NESDO and long-term prognosis of late-life depression. 2 
 3 
Figure 2. Symptom severity levels of depression (IDS) at six-month intervals according to the 4 
prognosis of depressed patients after six-year follow-up.   5 
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Table 1. Characteristics of N=201 depressed patients at baseline and according to their course type of late-life depression at follow-up.  
Baseline  Six-year follow-up, course types 
 
Prognostic factors 
Total 
N=201 
Full remission  
N=48 
Partial remission  
N=93 
Recurrent or Chronic 
N=60 
Demographics     
Women, N (%) 137 (68.2) 28 (58.3) 66 (71.0) 43 (71.7) 
Age, years, mean (SD) 69.0 (6.5) 68.4 (5.9) 69.5 (6.8) 68.5 (6.5) 
Education, years, mean (SD) 10.9 (3.5) 10.8 (3.1) 10.8 (3.4) 11.0 (4.0) 
Depression-related clinical factors     
Previous episode depression, yes, N (%) 175 (90.2) 41 (87.2) 80 (90.9) 54 (91.5) 
Age of onset of depression, mean (SD) 46.3 (19.7) 48.4 (18.3) 49.1 (18.5) 40.5 (21.4) 
Severity depressive symptoms, mean (SD) 29.7 (12.5) 26.0 (13.6) 28.5 (10.2) 34.5 (13.6) 
Comorbid anxiety diagnosis, yes, N (%) 79 (39.3) 17 (35.4) 30 (32.3) 32 (53.3) 
Severity anxiety symptoms, mean (SD) 16.8 (10.7) 14.3 (10.6) 15.6 (9.2) 20.6 (12.1) 
Global Cognitive Functioning, mean (SD) 28.1 (1.6) 28.1 (1.5) 28.3 (1.4) 27.8 (2.0) 
Apathy, mean (SD) 16.8 (5.3) 15.3 (5.2) 17.1 (5.4) 17.5 (5.2) 
Sleep problems, mean (SD) 10.9 (5.2) 11.0 (5.7) 10.6 (5.1) 11.3 (5.1) 
Use of antidepressants, yes, N (%) 145 (72.9) 37 (78.7) 58 (63.0) 50 (83.3) 
Frequent use of benzodiazepines, yes, N (%) 73 (36.3) 20 (41.7) 29 (31.2) 24 (36.3) 
Health and lifestyle factors     
Chronic diseases, mean (SD) 2.1 (1.5) 1.5 (1.0) 2.1 (1.5) 2.5 (1.8) 
Functional Limitations, mean (SD) 25.0 (12.3) 23.5 (11.9) 23.4 (11.2) 28.6 (13.7) 
Metabolic syndrome, original ATP III criteria, yes, N (%) 61 (30.3) 11 (22.9) 32 (34.4) 18 (30.0) 
Chronic Pain, yes, N (%)  111 (55.5) 23 (47.9) 48 (51.6) 40 (67.8) 
Body-Mass-Index, mean (SD) 26.1 (4.3) 25.1 (3.7) 26.3 (4.2) 26.6 (4.8) 
Physical activity, low, N (%) 47 (24.1) 13 (28.3) 15 (16.7) 19 (32.2) 
Smoking, yes, N (%) 47 (23.4) 10 (20.8) 24 (25.8) 13 (21.7) 
Alcohol, AUDIT, median (IQR) 2 (4) 2 (4) 3 (5) 0 (3) 
Psychological and social factors     
Neuroticism, mean (SD) 39.1 (6.2) 37.1 (5.9) 38.5 (4.9) 41.7 (7.4) 
Childhood Trauma Index, mean (SD) 1.0 (1.2) 0.9 (1.1) 1.0 (1.1) 1.2 (1.3) 
Partner, no, N (%) 95 (47.3) 20 (41.7) 48 (51.6) 27 (45.0) 
 27 
 
Loneliness, mean (SD) 6.6 (3.5) 4.8 (3.3) 7.0 (3.4) 7.5 (3.3) 
Social support, poor, N (%) 96 (48.0) 23 (48.9) 44 (47.3) 29 (48.3) 
Recent life events, mean (SD) 1.8 (1.3) 1.6 (1.3) 1.9 (1.4) 1.8 (1.3) 
SD = standard deviation; IQR = interquartile range; AUDIT = Alcohol Use Disorders Identification Test.  7 
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Table 2. Prognostic factors associated with long-term course types of late-life depression from bivariate analyses using multinomial logistic regression.  
 
 
Partial remission 
(ref: full remission) 
 Recurrent or Chronic 
(ref: full remission) 
 Recurrent or Chronic 
(ref: partial remission) 
Prognostic factors OR 95% CI Wald χ2 p-value  OR 95% CI Wald χ2 p-value  OR 95% CI Wald χ2 p-value 
Demographics               
Women 1.75  (0.84-3.62) 2.25 .13  1.81  (0.81-4.03) 2.09 .15  1.04  (0.51-2.12) 0.01 .93 
Age 1.03  (0.97-1.08) 0.89 .35  1.00  (0.94-1.06) 0.01 .95  0.98  (0.93-1.03) 0.88 .35 
Education 1.00  (0.90-1.11) 0.00 .99  1.02  (0.92-1.14) 0.15 .70  1.02  (0.93-1.12) 0.22 .64 
Depression-related clinical factors               
Previous episode depression, yes 1.46  (0.48-4.50) 0.44 .51  1.58  (0.45-5.54) 0.51 .47  1.08  (0.34-3.48) 0.02 .90 
Age of onset of depression 1.00  (0.98-1.02) 0.04 .84  0.98  (0.96-1.00) 4.11 .043  0.98  (0.96-0.99) 6.59 .010 
Severity depressive symptoms  1.02  (0.99-1.05) 1.36 .24  1.06  (1.02-1.10) 11.27 .001  1.04  (1.01-1.07) 8.07 .005 
Comorbid anxiety diagnosis, yes 0.87  (0.42-1.81) 0.14 .71  2.08  (0.96-4.54) 3.41 .065  2.40  (1.23-4.68) 6.60 .010 
Severity anxiety symptoms  1.01  (0.98-1.05) 0.46 .50  1.06  (1.02-1.10) 7.68 .006  1.04  (1.01-1.08) 6.99 .008 
Global Cognitive Functioning 1.08  (0.87-1.34) 0.45 .50  0.90  (0.72-1.13) 0.83 .36  0.84  (0.69-1.02) 3.16 .076 
Apathy 1.07  (1.00-1.14) 3.36 .067  1.08  (1.00-1.17) 4.24 .040  1.01  (0.95-1.08) 0.20 .66 
Sleep problems 0.99  (0.92-1.06) 0.17 .68  1.01  (0.94-1.09) 0.12 .73  1.03  (0.97-1.10) 0.73 .39 
Use of antidepressants, yes 0.46  (0.20-1.04) 3.45 .063  1.35  (0.51-3.58) 0.37 .55  2.93  (1.32-6.52) 6.94 .008 
Use of benzodiazepines, yes 0.63  (0.31-1.31) 1.53 .22  0.93  (0.43-2.02) 0.03 .86  1.47  (0.75-2.90) 1.25 .26 
Health and lifestyle factors               
Chronic diseases 1.42  (1.08-1.87) 6.15 .013  1.65  (1.23-2.21) 10.99 .001  1.16  (0.94-1.43) 1.95 .16 
Functional Limitations  1.00  (0.97-1.03) 0.00 .95  1.04  (1.00-1.07) 4.34 .037  1.04  (1.01-1.07) 6.29 .012 
Metabolic syndrome, yes 1.77  (0.80-3.92) 1.95 .16  1.44  (0.60-3.44) 0.68 .41  0.82  (0.41-1.64) 0.32 .57 
Chronic Pain, yes  1.16  (0.58-2.33) 0.17 .68  2.29  (1.04-5.03) 4.25 .039  1.97  (0.99-3.90) 3.83 .050 
Body-Mass-Index 1.08  (0.98-1.18) 2.57 .11  1.10  (1.00-1.21) 3.50 .061  1.02  (0.95-1.10) 0.23 .63 
Physical activity, low 0.51  (0.22-1.19) 2.45 .12  1.21  (0.52-2.80) 0.19 .66  2.38  (1.09-5.17) 4.75 .029 
Smoking, yes 1.32  (0.57-3.05) 0.43 .51  1.05  (0.42-2.66) 0.01 .92  0.80  (0.37-1.72) 0.34 .56 
Alcohol use 1.05  (0.95-1.16) 0.78 .38  0.89  (0.77-1.03) 2.43 .12  0.85  (0.75-0.97) 5.90 .015 
Psychological and social factors               
Neuroticism 1.04  (0.98-1.10) 1.53 .22  1.14  (1.06-1.22) 12.90 <.001  1.09  (1.03-1.16) 8.98 .003 
Childhood Trauma Index 1.11  (0.81-1.52) 0.39 .53  1.26  (0.90-1.76) 1.83 .18  1.14  (0.87-1.50) 0.88 .35 
Partner, no 0.67  (0.33-1.35) 1.25 .26  0.87  (0.41-1.88) 0.12 .73  1.30  (0.68-2.50) 0.64 .43 
Loneliness 1.20  (1.08-1.34) 10.78 .001  1.26  (1.11-1.42) 13.58 <.001  1.05  (0.94-1.16) 0.75 .39 
Social support, poor 0.94  (0.46-1.89) 0.03 .86  0.98  (0.46-2.10) 0.00 .95  1.04 (0.54-2.00) 0.02 .90 
Recent life events 1.24  (0.95-1.63) 2.45 .12  1.17  (0.88-1.57) 1.13 .29  0.95  (0.74-1.20) 0.21 .65 
OR = odds ratio; CI = confidence interval; degrees of freedom for Wald χ2 statistic = 1.  8 
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Table 3. Prognostic factors associated with higher symptom levels of depression during six years from bivariate and multivariate linear mixed models analyses.  
 Bivariate models  Multivariate models, group wise  Multivariate model, final 
Prognostic factors β (SE) p-value df.  β (SE) p-value df.  β (SE) p-value df. 
Demographics            
Women 2.24 (1.60) .16 198         
Age -0.03 (0.12) .79 199         
Education 0.04 (0.22) .87 199         
a) Depression-related clinical factors     group wise model a     
Previous episode depression, yes 7.70 (2.52) .003 191  -0.18 (2.19) .93 165     
Age of onset of depression -0.16 (0.04) <.001 193  -0.08 (0.03) .017 165  -0.06 (0.03) .040 166 
Severity depressive symptoms  0.55 (0.05) <.001 198  0.40 (0.06) <.001 167  0.32 (0.07) <.001 168 
Comorbid anxiety diagnosis, yes 3.73 (1.51) .014 198  0.88 (1.23) .48 165     
Severity anxiety symptoms  0.51 (0.06) <.001 189  0.22 (0.07) .002 168  0.11 (0.07) .11 170 
Global Cognitive Functioning  -0.57 (0.46) .22 201         
Apathy 0.69 (0.14) <.001 188  0.30 (0.12) .011 166  0.15 (0.12) .20 166 
Sleep problems 0.57 (0.14) <.001 190  -0.09 (0.13) .48 165     
Use of antidepressants, yes -0.52 (1.70) .76 196         
Use of benzodiazepines, yes -0.25 (1.56) .87 198         
b) Health and lifestyle factors     group wise model b     
Chronic diseases 2.70 (0.45) <.001 198  1.43 (0.43) .001 187  0.68 (0.39) .084 165 
Functional Limitations 0.41 (0.05) <.001 192  0.25 (0.06) <.001 187  -0.05 (0.06) .46 168 
Metabolic syndrome, yes 3.92 (1.61) .015 199  -0.68 (1.52) .66 188     
Chronic Pain, yes 7.80 (1.39) <.001 198  4.22 (1.32) .002 188  2.60 (1.21) .033 167 
Body-Mass-Index 0.81 (0.17) <.001 201  0.46 (0.17) .009 189  0.23 (0.14) .12 167 
Physical activity, low  -1.41 (1.79) .43 193         
Smoking, yes 0.92 (1.77) .60 198         
Alcohol use -0.47 (0.21) .025 196  -0.14 (0.18) .43 186     
c) Psychological and social factors     group wise model c     
Neuroticism 0.89 (0.11) <.001 188  0.73 (0.11) <.001 185  0.24 (0.12) .043 167 
Childhood Trauma Index 1.56 (0.64) .015 198  0.81 (0.55) .15 184     
Partner, no 1.15 (1.50) .44 198         
Loneliness 1.18 (0.21) <.001 188  0.70 (0.20) .001 185  0.39 (0.18) .036 166 
Social support, poor -0.19 (1.50) .90 197         
Recent life events 0.53 (0.56) .35 198         
β = regression coefficient; SE = standard error; df. = degrees of freedom, rounded to ones. p-values for the regression coefficients were generated with t-tests.  9 
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Multivariate group wise analyses contains factors that were associated with p<0.05 in bivariate analyses, for each domain (a-c). The final multivariate model contains all 10 
factors that were associated with p<0.05 in the multivariate group wise analyses (a-c). Goodness of fit: model a (χ2(7) = 2370.073, p<.001), model b (χ2(6) = 607.702, 11 
p<.001), model c (χ2(3) = 956.429, p<.001), final model (χ2(10) = 2042.444, p<.001). 12 
